P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a su... by Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman

P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial by Joseph F Merola, Subhashis Banerjee, Eric Morand, Piotr Leszczyński, Marilyn Pike, Ronald F van Vollenhoven, Coburn Hobar, Kathryn H Dao, Samantha Pomponi, Matthew J Colombo, Ravi Koti, Thomas Wegman